Tratamiento con tocilizumab en el síndrome de dificultad respiratoria aguda del adulto asociado a SARS COV-2

Tratamiento con tocilizumab en el síndrome de dificultad respiratoria aguda del adulto asociado a SARS COV-2

En 2019, en China se detectaron casos de una nueva patología causada por una variante desconocida, de la familia de los coronavirus, la cual presentó síntomas leves o incluso pacientes asintomáticos, se denominó SARS-CoV-2, pudiendo evolucionar a un síndrome de dificultad respiratoria aguda (SDRA),...

Full description

Bibliographic Details
Main Authors:	Diego Bratta, Franz Quezada
Format:	Article
Language:	Spanish
Published:	Universidad de Los Andes (Venezuela) 2023-07-01
Series:	Revista GICOS
Subjects:	tocilizumab síndrome de dificultad respiratoria del adulto covid-19 interleucina-6. tocilizumab adult respiratory distress syndrome interleukin-6
Online Access:	http://erevistas.saber.ula.ve/index.php/gicos/article/view/19171

Similar Items

Neumonía por COVID-19 y uso de tocilizumab
by: Ursula Cáceres-Bernaola, et al.
Published: (2020-07-01)

Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis
by: Marina Almenara-Tejederas, et al.
Published: (2022-01-01)

Síndrome de dificultad respiratoria aguda en niños
by: Valentin Santiago Rodríguez Moya, et al.
Published: (2019-02-01)

Tratamiento con Tocilizumab en COVID-19 crítico: Reporte de un centro hospitalario [Breve]
by: Miguel Hueda Zavaleta, et al.
Published: (2021-08-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
by: David Beauvais, et al.
Published: (2021-04-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Evaluación de tecnología sanitaria: informe de respuesta rápida. Tocilizumab para el tratamiento de la artritis idiopática juvenil poliarticular
by: Pablo García Munitis
Published: (2018-06-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

Espectro clínico de la Enfermedad de Castleman
by: María Rebeca Guzmán-Fernández, et al.
Published: (2014-12-01)

Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab
by: Jonathan P. Donnelly, et al.
Published: (2021-01-01)

Hemorragia pulmonar y síndrome de dificultad respiratoria aguda como complicaciones inusuales de la fiebre tifoidea
by: Francisco Cordié Muñoz, et al.
Published: (2017-06-01)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
by: Etienne Dufranc, et al.
Published: (2020-04-01)

Efficacy of Tocilizumab in Patients with COVID-19
by: Ahmad Alikhani, et al.
Published: (2022-12-01)

Appropriate use of tocilizumab in COVID-19 infection
by: Şiran Keske, et al.
Published: (2020-10-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
by: Sakkas LI
Published: (2016-08-01)

Successful Treatment of Recurrent Adult-Onset Still’s Disease with Tocilizumab: A Case Report and Literature Review
by: Zhong X, et al.
Published: (2023-11-01)

Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
by: Sibel BOLUKÇU, et al.
Published: (2021-01-01)

Tocilizumab In Severe To Critical Confirmed COVID-19: A Case Series At Ulin Referral Hospital Of South Kalimantan
by: Haryati Haryati, et al.
Published: (2021-06-01)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
by: Maxime Samson, et al.
Published: (2021-01-01)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)

Factores asociados al síndrome de dificultad respiratoria neonatal severa
by: Stefanía Loor Zambrano, et al.
Published: (2022-08-01)

2020 Updates on tocilizumab indications for clinicians managing patients with severe acute respiratory syndrome coronavirus 2
by: Mohammed A Omair, et al.
Published: (2020-01-01)

Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
by: Amanda Radulescu, et al.
Published: (2022-04-01)

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy
by: David J. Russell, et al.
Published: (2017-09-01)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
by: Ju-Yang Jung, et al.
Published: (2018-12-01)

Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis
by: Umesha Boregowda, et al.
Published: (2020-10-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Tocilizumab is effective in preventing ovarian injury induced by ischemia- reperfusion in rats
by: KEMINE UZEL, et al.
Published: (2023-05-01)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
by: Hiroki Wakabayashi, et al.
Published: (2019-04-01)

Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
by: Robert Szabo, et al.
Published: (2023-02-01)

Características clínicas de pacientes pediátricos con síndrome de dificultad respiratoria aguda asociado con COVID-19
by: María L. Marroquín-Yáñez, et al.
Published: (2022-07-01)

Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01)

Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
by: Zsófia Kardos, et al.
Published: (2023-01-01)

Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial
by: Tomohiro Koga, et al.
Published: (2018-12-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

Factores asociados a Síndrome de Dificultad Respiratoria del Recién Nacido del Hospital José Carrasco Arteaga. Estudio de casos y controles
by: Johana Alicia Palacios Sacoto, et al.
Published: (2020-12-01)

Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope
by: Jin Guo, et al.
Published: (2024-12-01)

Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
by: G. M. Koilubaeva, et al.
Published: (2022-05-01)